CoChat

Patient-derived organoids: a promising model for personalized cancer treatment

Open access
Yang, Huayu, Sun, Lejia, Liu, Meixi, Mao, Yilei · 2018 · Gastroenterology Report
Cited by 96

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Cancer has remained one of the biggest challenges for human health during the past few decades despite major advances in medicine [1]. Poor prognosis of cancer is mainly caused by a lack of effective treatment. Moreover, many patients cannot receive appropriate treatment despite early diagnosis. High heterogeneity is a tumor characteristic and different types of cancer usually vary in clinical features and tumorigenic mechanisms, which results in different responses to drugs [2]. How to predict accurately the patient’s response to drugs and choose personalized treatment is one of the main concerns of doctors. Cancer cell lines and patient-derived xenograft (PDX) models are widely used as preclinical tumor models for screening drugs and assessing drug responses. Cancer cell lines are derived from primary patient tumors and have contributed greatly to cancer research. Cancer cell lines are able to expand rapidly and are often used for high-throughput drug screening. Moreover, they are amenable to genetic modification, which is necessary for research on mechanisms of cancer development. However, it is clear that histological and genetic features in cancer cell lines have changed a lot compared with those in native tumors [3]. As a result, many drugs that perform well in cancer cell lines finally fail in clinical trials. PDX models are generated by transplanting fresh tumor tissue from patients subcutaneously or orthotopically into immunodeficient mice. They mimic the biological characteristics of the primary tumors better than do cancer cell lines. Although PDX models can better predict drug responses, their application in medicine is limited because they are expensive and time- and resource-consuming [4]. It is necessary to develop a new model that has the advantages of the two models mentioned above. Tumor organoids may be superior models to identify and test novel anticancer drugs. Organoids are 3D cultured multicellular clusters. They are derived from pluripotent stem cells or isolated organ progenitors that differentiate to form an organ-like tissue exhibiting multiple cell types. Organoids have self-renewal and self-organization capabilities and retain the characteristics of the physiological structure and function of their source tumor. Sato et al. [5] placed intestinal stem cells into a gel matrix to mimic the extracellular matrix microenvironment, and finally the stem cells began to divide, differentiate and form structures resembling intestinal villi and crypts. Since then, organoids have been widely studied. Upon embedment into a 3D matrix, tissue-derived tumors from patients can also grow into organoids, termed tumor organoids (Figure 1) [6]. So far, 12 tumor organoids have been established (Table 1) [7–16]. In a recent study, Vlachogiannis and colleagues [7] developed patient-derived organoids (PDOs) derived from 110 metastatic tumor samples from 71 patients with colorectal or gastroesophageal cancer enrolled in phase I/II clinical trials. Phenotypic and genotypic profiling of PDOs was similar to that of the original tumors and they had the same gene-mutation spectrum. Besides, molecular profiling of the tumor organoids was matched to drug-screening results. More importantly, PDOs had 88% accuracy for predicting whether they would respond to some drugs and 100% accuracy for predicting whether they would not. The outcomes of PDOs for predicting treatment are encouraging and suggest that PDOs may be an ideal platform to identify and assess the efficacy of anticancer drugs. Summary of patient-derived organoids Summary of patient-derived organoids Generation of patient-derived organoids. Cancer cells from patients are embedded into a matrix for 3D culture in vitro and they can grow into tumor organoids. Patient-derived organoids mimic the biological characteristics of the primary tumors. PDOs are 3D in vitro models; many studies have shown that they can recapitulate basic features of primary tumors, including histological complexity and genetic heterogeneity of human cancer [7–16]. Hematoxylin and eosin staining shows that PDOs share morphological features with the primary tumor and immunohistochemistry markers used in the diagnosis of specific tumors show that the expression pattern of the tumor is maintained in PDOs [7]. Moreover, PDOs preserve the genomic and transcriptomic characteristics of their primary tumors [7]. For example, mutation status, copy number alteration and identification of fusion genes and transcriptional landscape are similar to those of the primary tumor. These genomic alterations persist even after several months of subsequent culture. Compared with 2D culture models, the 3D models have advantages in gene expression, mutation status, metastatic potential and drug response. PDOs can also be expanded long-term in vitro and used for high-throughput drug screening. These characteristics of PDOs discussed above allow a wide range of potential applications in medicine (Figure 2). Fi

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/gastro/goy040

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 96

Metadata

Authors
Yang, H., Sun, L., Liu, M., & Mao, Y.
Venue
Gastroenterology Report
Published
2018-10-09
Volume
6
Issue
4
Pages
243-245
ISSN
2052-0034 (ISSN-L)
OpenAlex
W2899911867
Cited by
96
References
11
FWCI
2.44
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient-derived organoids: a promising model for personalized cancer treatment. https://app.cochat.ai/papers/10.1093/gastro/goy040
The paper
Yang, H., Sun, L., Liu, M., & Mao, Y. (2018). Patient-derived organoids: a promising model for personalized cancer treatment. Gastroenterology Report. https://doi.org/10.1093/gastro/goy040

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.